Paloma Partners’s Syndax Pharmaceuticals SNDX Stock Holding History

Paloma Partners’s Portfolio SNDX Stock Details SNDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-12,500	Closed	-$56K	–	1918
2018 Q4	$56K	Buy	+12,500	New	+$68.5K	﹤0.01%	1162
2018 Q2	–	Sell	-13,800	Closed	-$196K	–	2151
2018 Q1	$196K	Sell	13,800 -2,600	-16%	-$27.6K	﹤0.01%	1805
2017 Q4	$144K	Buy	+16,400	New	+$162K	﹤0.01%	1769

Other funds holding SNDX

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

MAM

MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

6CM

683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Paloma Partners's SNDX Position: Q1 2019 in Review

Paloma Partners sold out of Syndax Pharmaceuticals (SNDX) in Q1 2019, closing a stake of 12,500 shares — an estimated $56K sold.

Paloma Partners first reported a position in SNDX in Q4 2017 and held it in 3 quarters. The position peaked at $196K in Q1 2018. 69 funds tracked by Wall St. Rank hold SNDX as of Q1 2019.

Paloma Partners reported no remaining Syndax Pharmaceuticals position as of Q1 2019 after selling out during the quarter.
Paloma Partners sold 12,500 Syndax Pharmaceuticals shares in Q1 2019, an estimated $56K.
Paloma Partners first reported a position in Syndax Pharmaceuticals in Q4 2017 and held it in 3 quarters.
Paloma Partners's Syndax Pharmaceuticals position peaked at $196K in Q1 2018.
69 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q1 2019.

Based on Paloma Partners's 13F filing for Q1 2019, filed 15 May 2019.